Business Wire

Vantage Data Centers Completes Industry’s First Euro-Based Data Center Asset-Backed Securitization (ABS) with €640M Transaction

Share

Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised €640 million in securitized term notes, marking the first-ever euro-based securitization of data center assets in Continental Europe. The transaction includes an additional €80 million in unfunded Variable Funding Notes. The Class A-2 Notes are rated A-, and the Class B Notes are rated BBB- by Standard & Poor’s and Scope Ratings. This transaction follows Vantage’s success last year with the first-ever EMEA data center ABS completed in British pound sterling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609592365/en/

Pictured is BER11, part of Vantage’s first Berlin campus located in Brandenburg Park.

The notes will be used to refinance four data centers in Germany, two in Offenbach, Frankfurt, and two in Berlin, all of which are fully leased to hyperscale customers. The refinancing is part of Vantage’s wider efforts to further expand its presence in the EMEA region and accelerate time to market to meet mounting demand for AI and cloud capacity. Surplus funds will be allocated toward capital expenditures and broader corporate initiatives. The notes have an anticipated five-year repayment date.

“The issuance of the first euro-denominated ABS in the data center sector marks a significant milestone in digital infrastructure financing. Having previously issued the first data center ABS in both North America and EMEA (sterling-denominated), Vantage continues to showcase our innovative approach to capital markets and our ability to unlock new funding vehicles to fuel our global expansion,” said Rich Cosgray, senior vice president, global capital markets for Vantage Data Centers.

Vantage was represented by Clifford Chance LLP, and the transaction was led by Barclays and Deutsche Bank as active Joint Lead Managers. The transaction was supported by ING and Natixis as Joint Lead Managers and ABN Amro, Banco De Sabadell, SMBC and Societe Generale as Co-Managers.

Barclays acted as Sole Structuring Advisor and Sole Green Structuring Advisor, and the transaction achieved a Green Bond designation via a Second-Party Opinion (SPO) from Morningstar Sustainalytics. The funds raised will contribute to advancing the United Nations Sustainable Development Goals (SDGs) and will facilitate the innovation of next-generation sustainable solutions aimed at reducing Vantage’s environmental impact. For more information, please refer to the company’s Green Bond Framework.

Over the last 12 months, Vantage has raised €2.2 billion in new debt financing for its EMEA platform.

For more information about Vantage’s growing EMEA footprint, please visit: https://vantage-dc.com/data-center-locations/emea/.

About Vantage Data Centers

Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.

For more information, visit http://www.vantage-dc.com.

Nothing in this press release constitutes an offer to sell or the solicitation of an offer to buy the notes in any jurisdiction, and there shall not be any sale of the notes in any state or jurisdiction in which the offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250609592365/en/

Contacts

Press Contacts
Mark Freeman
Vantage Data Centers
mfreeman@vantage-dc.com
+1-202-680-4243

Robin Bectel
REQ for Vantage Data Centers
vdc@req.co
+1-202-936-6335

Nigel Parker
Fulfil Communications for Vantage Data Centers, EMEA
nigelp@fulfilcom.com
+44-(0)-7778-872-457

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Uniphore Launches Business AI Cloud: A Sovereign, Composable & Secure AI Platform to Power the Agentic Enterprise9.6.2025 16:04:00 EEST | Press release

Uniphore, the Business AI company, today launched the Uniphore Business AI Cloud: a sovereign, composable, and secure platform that bridges the “AI divide” between IT and business users by combining the simplicity of consumer AI with enterprise-grade security and scalability. While AI technologies rapidly reshape the enterprise, there has been little focus on deploying AI in a way that empowers CIOs to scale it securely across the organization while enabling business users to intuitively access AI with the full power of enterprise data, integrations, and context. IT and business must be united through a single AI platform to fulfill AI’s promise as a transformative force for business. Introducing the Business AI Cloud Uniphore’s Business AI Cloud powers the agentic enterprise with a full-stack AI platform spanning data, knowledge, models, and agents. It empowers business users to deploy AI agents and tap into enterprise knowledge instantly, while giving CIOs the foundation to deliver s

Capcom’s Resident Evil Requiem , the Latest Title in the Series, Set to Release on February 27, 2026!9.6.2025 16:00:00 EEST | Press release

Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series, is scheduled for release on February 27, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609946595/en/ Resident Evil Requiem Logo Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development expertise cultivated through numerous hit titles. The graphical fidelity has undergone a significant evolution in particular, delivering visuals with cinematic realism that vividly convey characters’ emotions and offer an unprecedented level of immersion. The company is developing the title steadily to meet the high expectations of both long-time series’ fans and the global gaming audience. Further details regarding the title will be announced in

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND ® in Rare Blood Disorders9.6.2025 15:40:00 EEST | Press release

Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, the UK and Switzerland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609510947/en/ Adam Plich, Founder & CEO “This partnership marks a major milestone in our mission to transform how rare disease therapies reach patients in Europe,” said Adam Plich, Founder and CEO of Avanzanite. “We provide biotech partners with a capital-efficient path to sustainable patient access – without the burden of building a costly local infrastructure. We

Tier-1 MVNO Selects Tecnotree’s AI-Native BSS for Multi-Country Transformation Across UK & Europe9.6.2025 15:36:00 EEST | Press release

Tecnotree, the global pioneer in AI-native Digital BSS and fintech platforms, has announced a major multi-year, multi-country agreement with a Tier-1 Mobile Virtual Network Operator (MVNO) to transform its operations across the United Kingdom and Europe. The deal, valued at USD 19.58 million over five years, positions Tecnotree at the forefront of next-generation MVNO enablement in mature, highly competitive telecom markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609328949/en/ This engagement will see the full-stack replacement of the MVNO’s legacy systems with Tecnotree’s composable, cloud-native BSS—an AI-first, TM Forum ODA-aligned platform engineered for speed, scale, and interoperability. Designed to unlock real-time personalization, agile service orchestration, and embedded financial ecosystems, this transformation lays the foundation for the MVNO to compete with intelligence and grow with intent. The deploy

Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic9.6.2025 15:00:00 EEST | Press release

Innospera Pharma Inc. (“Innospera”), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company’s lead compound reaches the clinic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609975546/en/ Glenn Crater, MD, FCCP, appointed Chief Medical Officer of Innospera Pharma Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Inno

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye